November 15, 2024

Whistle-Blowers in Limbo, Neither Hero Nor Traitor

Even as Americans expressed increasing concerns about government intrusions into their life in a recently released Pew Research Center study, they have hardly embraced those who decide to take matters into their own hands.

Leakers, often lionized by members of the press, face an indifferent and sometimes antagonistic public.

On Tuesday, when Pfc. Bradley Manning was acquitted of aiding the enemy and convicted of six counts of violating the Espionage Act, a few dozen protesters showed up on his behalf. There has been an outcry from civil libertarians and privacy advocates, but in general, his decision to unilaterally release hundreds of thousands of sensitive documents did not make him a folk hero or a cause célèbre in the broader culture.

Edward Snowden, the former National Security Agency employee, also released a trove of documents, including ones revealed on Wednesday in The Guardian that suggested that security analysts are able to search through e-mails, chats and browsing history without judicial authorization. Even though many people are glad to learn that, Mr. Snowden remains very much on his own in the Moscow airport — stateless, isolated and frozen in place for the time being.

In some respects, Mr. Snowden and Private Manning were performing a quintessentially American act: lone individuals taking on larger forces. But whistle-blowing has always been fraught with peril; one person’s heroic crusade is another’s betrayal of loyalty. In the case of both Mr. Snowden and Private Manning, each became an army of one, reasoning that there was a moral imperative to rendering secrets visible, acting on behalf of a public that he believed deserved to know more. But some Americans don’t seem ready to embrace this version of informational cowboy.

“Who is he to decide?” suggested a cabdriver in New York on Tuesday, speaking of Private Manning. He could have been speaking of Mr. Snowden as well.

In the view of advocates of civil liberties, both men performed acts of supreme self-sacrifice, but there is an unavoidable appearance of self-aggrandizement as well. We have been treated to hundreds of images of Mr. Snowden and Private Manning.

“Whistle-blowers they are not. These are essentially little people with bloated egos and sense of self-importance,” suggested one reader in comments that appeared with The New York Times’s article about Private Manning’s conviction.

Part of the reason that both men have gotten so much attention is that the Web has made the gathering and dissemination of large amounts of information much easier than it was in the past. Rather than slipping an envelope under a door, many of today’s leakers operate using hard drives jammed with millions of documents. It is far easier to do much more damage, something both the government and the public are struggling to come to terms with.

“The more they reveal, the greater the threat against them,” said Gregg Leslie of the Reporters Committee for Freedom of the Press, referring to large-scale whistle-blowers.

The mixed feelings evoked by those who perform jailbreaks on information was very much in evidence in a report released by M.I.T. on the same day that Private Manning was convicted. The report concluded that in the case of Aaron Swartz, the hacker who committed suicide after being charged with hacking into the M.I.T. computer network, the university “missed an opportunity to demonstrate the leadership that we pride ourselves on.” The report noted that the university had based on its reputation as an institution known “for promoting open access to online information, and for dealing wisely with the risks of computer abuse.”

Time can change things. Daniel Ellsberg, who came in for sustained criticism for his leak of the Pentagon Papers, is now viewed as an important historical figure who brought much-needed accountability to America’s prosecution of the Vietnam War. But for the time being, Private Manning and Mr. Snowden are legally imperiled and living in the place between hero and traitor. As Bill Keller, the former executive editor of The New York Times, said on Wednesday morning on WNYC’s “The Takeaway,” they are “neither Benedict Arnold nor Nathan Hale.”

Article source: http://www.nytimes.com/2013/08/01/business/media/whistle-blowers-in-limbo-neither-hero-nor-traitor.html?partner=rss&emc=rss

For Drug Makers, China Becomes a Perilous Market

The booming Chinese demand for drugs couldn’t come at a better time for Western manufacturers, whose sales have been slumping because of patent expirations in the United States and stringent price controls in Europe.

But selling pharmaceuticals and other health care products in China is increasingly fraught with peril, as shown by allegations in China this week that GlaxoSmithKline funneled payments through travel agents to doctors, hospitals and government officials to bolster drug sales in the country.

Chinese officials have compared the company’s operations to organized crime and have detained four Chinese executives for questioning. Shortly after government investigators raided the British drugmaker’s Shanghai offices last month, the British executive in charge of the company’s Chinese operations left the country. He hasn’t been back since.

Earlier this month, the top manufacturers of infant formula, including Abbott and Nestlé, lowered their prices in China under government pressure, and Chinese officials have said they are investigating the pricing policies of up to 60 foreign and domestic drug companies.

The rash of investigations is one measure of how critical the health care market has become to global companies — and to the Chinese government. The Chinese have made no secret of their goal of pushing the country’s domestic drug industry into more direct competition with the world’s top manufacturers.

As a result, global companies can expect more scrutiny, said Tarun Khanna, a professor at Harvard Business School who has studied foreign investment in China.

“Practices that may have been O.K. some time back may be more scrutinized by foreigners now,” he said, especially as the government seeks to shift from an export-based economy to one that is also focused on selling to Chinese consumers. “They’re trying to get more balance back.”

Several factors are contributing to the boom in China, experts said. China’s growing economy has given rise to a middle class that is increasingly able to afford expensive Western drugs, and to treat conditions – such as depression and respiratory illnesses – that may have otherwise gone undiagnosed or unmedicated.

And under a new health care program, China has expanded insurance coverage to hundreds of millions of new patients – 95 percent of the population had insurance in 2011, compared to 43 percent in 2006, according to a recent report by the consulting firm McKinsey Company. By 2020, China’s total spending on health care is expected to grow to $1 trillion, from $357 billion in 2011, according to McKinsey.

Even as foreign companies raise their investment, the Chinese are also looking to capitalize on the booming health care market. The government identified the medical industry as one of seven key areas for development in its most recent five-year economic plan, and the country’s medical sector invested $160 billion in research and development in 2012, nearly surpassing Japan, according to a recent report by the Boston-based Lux Research.

“China is interested in building a very strong, homegrown industry,” said Kevin Pang, a research director at Lux.

But some believe Western companies will have an edge because consumers may be willing to pay more for brands that are known for high-quality ingredients.

“There are so many drugs that are poor quality in China, so the ability to differentiate yourself is important,” said Craig A. Wheeler, the chief executive of the American generic drug maker Momenta Pharmaceuticals. His company is developing complex drugs known as biosimilars through a business deal with Baxter, which has an established presence in China.

Mr. Wheeler said the recent crackdowns are to be expected. “These markets are maturing, and these markets are going to be therefore more highly regulated,” he said.

The bribery investigation into GlaxoSmithKline comes as the company has been struggling to rebuild its image in the wake of a historic $3 billion fine in the United States last year, in which the company admitted to improperly promoting its antidepressants and failing to report safety data about the diabetes drug Avandia. Andrew Witty, who took over as chief executive in 2008, has repeatedly pitched the company as a global leader in ethical practices and said it has moved on from its previous lapses.

Article source: http://www.nytimes.com/2013/07/17/business/global/for-drug-makers-china-becomes-a-perilous-market.html?partner=rss&emc=rss